Therefore, inhibitors targeting PI3K/AKT signaling pathway, e.g., alpelisib, inavolisib, ipatasertib, MK-2206 and sirolimus, could significantly prolong the survival of patients with HR+ advanced breast cancer 5-7. Here, PIK3CA is linked to breast cancer.